Donafenib: all 41 studies that test it

Page 1 of 1. Open to participants first (14), then studies with results posted, then the rest; newest registration first within each.

• A Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Targeted Therapy and a PD-1 Inhibitor in Patients With Postoperative Hepatocellular Carcinoma and Microvascular InvasionNot yet recruitingNCT07790419Phase 4
• The DoHAICs Study Expansion PhaseNot yet recruitingNCT07584018Phase 2
• Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and DiabetesNot yet recruitingNCT07557914Phase 2
• FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic CholangiocarcinomaNot yet recruitingNCT07353827Phase 2
• HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of RecurrenceRecruitingNCT06812039Phase 2
• Donafenib Combined With Capecitabine for Postoperative Adjuvant Therapy of Biliary Malignant Tumors With High-risk Recurrence RiskRecruitingNCT06685289Phase 2
• TIPS Plus Half-dose Donafenib in AHCC with PVTT-associated Portal HypertensionRecruitingNCT06646198Phase 2
• Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCCRecruitingNCT06609876Not applicable
• Postoperative Adjuvant Therapy of Donafenib for Hepatocellular CarcinomaRecruitingNCT06581315Not applicable
• Donafenib Combine With Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular CarcinomaNot yet recruitingNCT06512467Phase 2
• Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With EnvafolimabRecruitingNCT06498622Phase 2
• Donafenib Combined With Immunotherapy and Local Therapy for Unresectable Hepatocellular Carcinoma That Has Failed in Previous TherapyNot yet recruitingNCT06496815Phase 4
• Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid CancerRecruitingNCT06482086Phase 2
• A Study Evaluating the Efficacy and Safety of ZG005 in Combination With Donafenib or Bevacizumab in Patients With Advanced Hepatocellular CarcinomaNot yet recruitingNCT06233994Not applicable
• A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid TumorStatus unknownNCT06239298Phase 1/2
• Donafenib Combined With Hepatic Artery Chemoembolization for Perioperative Treatment of Liver TransplantationStatus unknownNCT05576909Phase 2
• Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of RecurrenceStatus unknownNCT05545124Phase 2
• HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCCStatus unknownNCT05493332Phase 2
• HAIC Combined With Toripalimab and Donafenib for Advanced BTCStatus unknownNCT05350943Phase 2
• A Single Center Study of Donafenib Combined With PD-1 + TACE in the First-line Treatment of aHCCCompletedNCT05262959Phase 2
• Donafenib Combine With Sintilimab and HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）in the First-line Treatment of Unresectable Hepatocellular CarcinomaStatus unknownNCT05166772Phase 2
• Donafenib Plus Sintilimab for Advanced HCCCompletedNCT05162352Phase 2
• Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular CarcinomaStatus unknownNCT05161143Phase 2
• A Study of Donafenib Plus S-1 in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With Nab-paclitaxel Plus Gemcitabine RegimenStatus unknownNCT05138159Phase 2
• Clinical Study of Radiotherapy Combined With Donafenib for Neoadjuvant Treatment of Patients With HCC With Portal Vein Carcinoma ThrombosisStatus unknownNCT05022628Phase 4
• Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After SurgeryCompletedNCT04962958Phase 2
• The Mass Balance and Biotransformation of [14C]Donafenib in Healthy Adult ManCompletedNCT04816123Phase 1
• A Phase 1/2 Study of Donafenib in Combination With KN046 in Advanced Gastrointestinal TumorsTerminatedNCT04612712Phase 1/2
• Toripalimab Combined With Donafenib in the Treatment of Advanced Hepatocellular CarcinomaStatus unknownNCT04503902Phase 1/2
• A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid TumorsStatus unknownNCT04472858Phase 1
• Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AMLTerminatedNCT04402723Phase 1
• Treatment of Non-small Cell Lung Cancer With PD-1 Monoclonal Antibody Combined With Donafenib Toluene SulfonateStatus unknownNCT04059874Phase 1
• A Phase 3 Study of Donafenib in Patients With Radioiodine-refractory Differentiated Thyroid CancerTerminatedNCT03602495Phase 3
• Donafenib for Previously Treated Metastatic Colorectal CancerCompletedNCT02870582Phase 3
• Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid CancerCompletedNCT02870569Phase 2
• Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal CarcinomaTerminatedNCT02698111Phase 1/2
• Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular CarcinomaCompletedNCT02645981Phase 2/3
• Donafenib Monotherapy for Previously Treated Metastatic Colorectal CancerCompletedNCT02489916Phase 1/2
• Donafenib Monotherapy for Previously Treated Metastatic Gastric CancerTerminatedNCT02489214Phase 1/2
• A Study of Donafenib Monotherapy in Advanced Oesophageal CancerTerminatedNCT02489201Phase 1/2
• Safety and Efficacy of Donafenib in Patients With Advanced Hepatocellular CarcinomaCompletedNCT02229071Phase 1/2

← Donafenib overview